JPS63229068A - Electric stimulation wound treatment apparatus - Google Patents
Electric stimulation wound treatment apparatusInfo
- Publication number
- JPS63229068A JPS63229068A JP6192987A JP6192987A JPS63229068A JP S63229068 A JPS63229068 A JP S63229068A JP 6192987 A JP6192987 A JP 6192987A JP 6192987 A JP6192987 A JP 6192987A JP S63229068 A JPS63229068 A JP S63229068A
- Authority
- JP
- Japan
- Prior art keywords
- stimulation
- wound treatment
- electrical stimulation
- electrode
- treatment device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000638 stimulation Effects 0.000 title claims description 116
- 238000011282 treatment Methods 0.000 title claims description 72
- 208000027418 Wounds and injury Diseases 0.000 title claims description 57
- 206010052428 Wound Diseases 0.000 title claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 10
- 210000000416 exudates and transudate Anatomy 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 239000011591 potassium Substances 0.000 claims description 10
- 239000000645 desinfectant Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000003410 keratolytic agent Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 5
- 239000003071 vasodilator agent Substances 0.000 claims description 5
- 239000000701 coagulant Substances 0.000 claims description 4
- 230000002797 proteolythic effect Effects 0.000 claims description 4
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 4
- 239000006096 absorbing agent Substances 0.000 claims description 3
- 239000003792 electrolyte Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 description 20
- 238000010586 diagram Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000004210 Pressure Ulcer Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 4
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 206010072170 Skin wound Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003990 capacitor Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002239 ischium bone Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 oral drugs Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 206010008528 Chillblains Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910000856 hastalloy Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Electrotherapy Devices (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、創傷や皮膚と毛髪等その付属部の障害治療を
行う電気刺激創傷治療装置に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to an electrical stimulation wound treatment device for treating wounds and disorders of the skin and its appendages such as hair.
従来、皮膚における創傷あるいは皮膚とその付属器の障
害の治療法としては、皮膚外用薬、経口薬、注射薬など
による薬物療法あるいは外科的治療法が主たるものであ
る。BACKGROUND ART Conventionally, the main treatments for wounds on the skin or disorders of the skin and its appendages have been drug therapy using topical skin drugs, oral drugs, injection drugs, etc., or surgical treatments.
このうち、皮膚創傷の局所治療剤として使われている皮
膚外用薬は、その原因、程度その他の要因によって異な
るが、通常は消毒剤、抗菌剤、抗生物質、抗炎症剤、蛋
白分解酵素、凝固剤、浸出液吸収剤、ビタミン剤、ホル
モン剤などを目的に応じて混合した組成よりなる。Among these, topical skin drugs used as topical treatment agents for skin wounds vary depending on the cause, severity, and other factors, but are usually disinfectants, antibacterial agents, antibiotics, anti-inflammatory agents, proteolytic enzymes, coagulants, etc. It consists of a mixture of agents, exudate absorbents, vitamins, hormones, etc. depending on the purpose.
一方、広範囲で深部組織ムこ達する重度の火傷、熱傷、
褥創、外傷等の皮N損傷では、強度の炎症反応、局所循
環障害、感染等が生し、単にこれらの薬剤のみでは治療
に反応しないことが多い。この場合、外科的に縫合した
りもしくは植皮することが最善の治療法として行われて
いるのが通常である。また近年は、重度の褥創に対して
、顕著な肉芽形成効果があるとして、糖が褥創治療剤と
して使われ始めている。On the other hand, severe burns that affect deep tissues over a wide area,
Skin injuries such as bedsores and trauma cause strong inflammatory reactions, local circulation disorders, infections, etc., and these drugs alone often do not respond to treatment. In this case, surgical suturing or skin grafting is usually the best treatment. In recent years, sugar has also begun to be used as a therapeutic agent for severe bedsores, as it has a remarkable granulation-forming effect.
他方、皮膚角化症、各種皮膚炎、後天性色素異常症、湿
疹、肌あれ、鮫肌、シミ、にきび、ひび、あかぎれ、お
むつかぶれ、しもやけ等の皮膚障害に対する薬剤には、
角質溶解剤(サルチル酸等)、ビタミン剤、消炎剤、ホ
ルモン剤および種々の基薬等が目的に応じて配合されて
いる。On the other hand, drugs for skin disorders such as skin keratosis, various dermatitis, acquired pigment abnormalities, eczema, rough skin, shark skin, age spots, acne, cracks, chapping, diaper rash, chilblains, etc.
Keratolytic agents (such as salicylic acid), vitamins, anti-inflammatory agents, hormones, and various base agents are blended depending on the purpose.
また、白毛、脱毛症などの毛髪疾患に対して、血管拡張
剤、ビタミン剤、ホルモン剤などが養毛、発毛として従
来より使用されている。Additionally, vasodilators, vitamins, hormones, and the like have been conventionally used for hair growth and hair growth for hair diseases such as gray hair and alopecia.
上記のごとく、薬物および外科的療法が、皮膚創傷、皮
膚とその付属器の障害の主たる治療法であり、電気刺激
法が皮膚創傷、皮膚とその付属器の障害に著明な治療効
果を持つことは知られてぃない。また、皮膚外用薬とし
ても、糖やカリウムおよびその他の上記支店疾患治療剤
を混合した薬剤が、支店創傷、皮膚とその付属器の障害
に著明な治療効果を持つことは知られていない。As mentioned above, drug and surgical therapy are the main treatments for skin wounds and disorders of the skin and its appendages, and electrical stimulation has a significant therapeutic effect on skin wounds and disorders of the skin and its appendages. That is not known. Moreover, as an external skin drug, it is not known that a drug containing sugar, potassium, and other therapeutic agents for branch diseases mentioned above has a significant therapeutic effect on branch wounds and disorders of the skin and its appendages.
そこで、本願の発明者は、皮膚への電気刺激および糖や
カリウムを含有する皮膚外用薬によって、その創傷治療
効果および皮膚とその付属器の障害の治療効果について
種々検討を加え、従来の薬物療法や外科的治療法に匹敵
あるいはそれを超える治療効果をもたらす治療剤や治療
法および治療装置を見出すべく研究を行ってきた。Therefore, the inventor of the present application conducted various studies on the effect of electrical stimulation on the skin and topical skin drugs containing sugar and potassium for treating wounds and disorders of the skin and its appendages, and compared conventional drug therapy. Research has been conducted to find therapeutic agents, methods, and therapeutic devices that have therapeutic effects that are comparable to or exceed those of surgical and surgical treatments.
本発明は、上記の研究の成果に基づ(ものであって、電
気刺激を使うことによって、さらには糖とカリウムの混
合剤を電気刺激と併せ使用することによって高い治療効
果を得ることができる電気刺激創傷治療装置を提供する
ことを目的とするものである。The present invention is based on the results of the above research, and it is possible to obtain high therapeutic effects by using electrical stimulation, and by using a mixture of sugar and potassium in conjunction with electrical stimulation. An object of the present invention is to provide an electrical stimulation wound treatment device.
そのために本発明の電気刺激創傷治療装置は、治療患部
に使用する刺激電極、該刺激電極に対置される不関電極
、及び刺激電極と不関電極との間に電気刺激を与える刺
激信号発生手段からなることを特徴とするものである。For this purpose, the electrical stimulation wound treatment device of the present invention includes a stimulation electrode used for the treatment affected area, an indifferent electrode placed opposite to the stimulation electrode, and a stimulation signal generating means for applying electrical stimulation between the stimulation electrode and the indifferent electrode. It is characterized by consisting of.
本発明の電気刺激創傷治療装置では、刺激信号発生手段
の信号によって刺激電極と不関電極を通して治療患部に
電気刺激を与えることによって高い治療効果を得ること
ができる。しかも創傷治療剤と併用して電気刺激を与え
ることによって相乗的に治療効果を高めることができる
。特に創傷治療剤として少なくとも糖とカリウム、さら
に、消毒剤、抗菌剤、抗生物質、抗炎症剤、ビタミン剤
、蛋白分解酵素、浸出液吸収剤、ホルモン剤、角質融解
剤、血管拡張剤、蛋白分解阻止剤、凝固剤、基剤を選択
的に混和し、また、塩化ナトリウム等の電解質を添加す
ることによって、さらに治療効果を高めることができる
。In the electrical stimulation wound treatment device of the present invention, a high therapeutic effect can be obtained by applying electrical stimulation to the treated area through the stimulation electrode and the indifferent electrode using the signal from the stimulation signal generating means. Moreover, by applying electrical stimulation in combination with a wound treatment agent, the therapeutic effect can be synergistically enhanced. At least sugar and potassium, especially as wound treatment agents, as well as disinfectants, antibacterial agents, antibiotics, anti-inflammatory agents, vitamins, proteolytic enzymes, exudate absorbers, hormonal agents, keratolytic agents, vasodilators, and proteolytic inhibitors. The therapeutic effect can be further enhanced by selectively mixing agents, coagulants, and bases, and by adding electrolytes such as sodium chloride.
以下、図面を参照しつつ実施例を説明する。 Examples will be described below with reference to the drawings.
第1図は本発明に係る電気刺激創傷治療装置の1実施例
を説明するための図、第2図は本発明に係る電気刺激創
傷治療装置の他の実施例を説明するための図である。図
中、1と14は不関電極、2と13は刺激用電極、3は
シート電池、4は電気刺激回路、11は電気刺激装置、
12と15はコネクタ、16は生体を示す。FIG. 1 is a diagram for explaining one embodiment of the electrical stimulation wound treatment device according to the present invention, and FIG. 2 is a diagram for explaining another embodiment of the electrical stimulation wound treatment device according to the present invention. . In the figure, 1 and 14 are indifferent electrodes, 2 and 13 are stimulation electrodes, 3 is a sheet battery, 4 is an electrical stimulation circuit, 11 is an electrical stimulation device,
12 and 15 are connectors, and 16 is a living body.
第1図において、電気刺激回路4は、シート電池3を電
源として不関電極1と刺激用電極2との間に微弱な直流
刺激やパルス刺激や交流刺激等の信号を発生させるもの
であり、簡単な定電流回路やパルス発生回路により構成
できるので、小型のICチップを使用することができる
。刺激用電極2は、創傷治療剤の層を有し、患部を創傷
治療剤で覆って電気刺激を与えるものであり、不関電極
1は、例えば導電性のゴム等を用い非刺激側の電極とし
て皮膚表面に貼り付けられるものである。In FIG. 1, an electrical stimulation circuit 4 uses a sheet battery 3 as a power source to generate signals such as weak direct current stimulation, pulse stimulation, and alternating current stimulation between an indifferent electrode 1 and a stimulating electrode 2. Since it can be configured with a simple constant current circuit or pulse generation circuit, a small IC chip can be used. The stimulation electrode 2 has a layer of a wound treatment agent and applies electrical stimulation to the affected area by covering it with the wound treatment agent.The indifferent electrode 1 is made of, for example, conductive rubber and is an electrode on the non-stimulation side. It is attached to the skin surface as a mask.
不関電極1、刺激用電極2、シート電池3、電気刺激回
路4を図のように1枚のシートにし、患部に貼着できる
ように構成すると、使い捨てとして用いることができる
。If the indifferent electrode 1, the stimulation electrode 2, the sheet battery 3, and the electrical stimulation circuit 4 are made into one sheet as shown in the figure and configured to be attached to the affected area, it can be used as a disposable sheet.
刺激用電極部分のみを使い捨ての構成にした本発明の他
の実施例を示したのが第2図である。第2図において、
刺激用電極13、不関電極14は、それぞれ電気刺激装
置11とコネクタ12.15によって接続するように構
成される。刺激用電極13は、糸状の電極を矩形のガー
ゼに隅から放射状に伸びるように織り込んだものであっ
て、自由なサイズにカットして使用できるように構成し
たものである。FIG. 2 shows another embodiment of the present invention in which only the stimulation electrode portion is disposable. In Figure 2,
The stimulation electrode 13 and the indifferent electrode 14 are configured to be connected to the electrical stimulation device 11 through connectors 12.15, respectively. The stimulation electrode 13 is made by weaving thread-like electrodes into rectangular gauze so as to extend radially from the corners, and is configured so that it can be cut to any size and used.
刺激用電極は、例えば8μ〜15μ程度のステンレスフ
ァイバー(SUS 316L)やハステロイファイバ
ー等、生体に毒性のない材料を用いたものである。そし
てこれらの材料を用いることにより、糸状に撚り、表面
にテフロンやシリコン等による被覆を施し、種々の形状
を採用できることは勿論である。The stimulation electrode is made of a material that is not toxic to the living body, such as stainless steel fiber (SUS 316L) or Hastelloy fiber with a diameter of about 8 μ to 15 μ, for example. By using these materials, it is of course possible to twist them into threads, coat the surface with Teflon, silicone, etc., and adopt various shapes.
第3図はシート状の刺激用電極による治療例を示す図、
第4図は糸状の刺激用電極による治療例を示す図、第5
図は電極の形状例を示す図、第6図は外科的に縫合した
部分の治療例を示す図である。図中、21と31は覆い
、22は刺激用電極、23と33は創傷治療剤、32は
糸状電極、41はファイバー露出部、42は被覆、43
はコネクタ部、51は縫合部、52は縫合糸、53はリ
ード線、54は電気刺激装置を示す。Figure 3 is a diagram showing an example of treatment using a sheet-shaped stimulation electrode;
Figure 4 is a diagram showing an example of treatment using a filamentous stimulation electrode;
The figure shows an example of the shape of the electrode, and FIG. 6 shows an example of treatment of a surgically sutured part. In the figure, 21 and 31 are covered, 22 is a stimulating electrode, 23 and 33 are wound treatment agents, 32 is a thread electrode, 41 is a fiber exposed part, 42 is a covering, 43
51 is a connector portion, 51 is a suture portion, 52 is a suture thread, 53 is a lead wire, and 54 is an electrical stimulation device.
第3図に示す例は、創傷部に創傷治療剤23を塗り、そ
の上にファイバー織り込みガーゼ等の刺激用電極22を
置き、その上に覆い21をのせたものである。この刺激
用電極22と不関電極との間に微弱な直流電流やパルス
電流や交流電流等を流すことによって、創傷治療剤23
を併用した電気刺激治療を行うものである。In the example shown in FIG. 3, a wound treatment agent 23 is applied to the wound area, a stimulation electrode 22 such as fiber-woven gauze is placed on top of the wound treatment agent 23, and a cover 21 is placed on top of the stimulation electrode 22. By passing a weak direct current, pulsed current, alternating current, etc. between the stimulation electrode 22 and the indifferent electrode, the wound treatment agent 23
Electrical stimulation therapy is performed in combination with
第4図に示す例は、創傷部に創傷治療剤33を塗ると共
にその中に糸状電極32を配置して刺激用電極とし、そ
の上にガーゼ等の覆い31を配置するものである。この
ような糸状電極の構成例を示したのが第5図である。す
なわち、第5図に示す糸状電極は、先端の例えば1cm
〜数cmだけ被覆を剥いでファイバー露出部41とし、
創傷部に挿入され刺激部となる。そして、コネクタ部4
3までの間はテフロンやシリコン等の被覆42を施し、
コネクタ部43を第2図に示すような電気刺激装置に接
続する。In the example shown in FIG. 4, a wound treatment agent 33 is applied to the wound area, a thread electrode 32 is placed therein to serve as a stimulation electrode, and a covering 31 such as gauze is placed on top of the wound treatment agent 33. FIG. 5 shows an example of the structure of such a thread-like electrode. That is, the thread-like electrode shown in FIG.
~ Peel off the coating by a few cm to make the fiber exposed part 41,
It is inserted into the wound and acts as a stimulation part. And the connector part 4
Until 3, apply a coating 42 of Teflon, silicone, etc.
Connector section 43 is connected to an electrical stimulation device as shown in FIG.
上記の例は、いずれも創傷部に創傷治療剤を塗り、刺激
用電極を配置して創傷部を覆うようにしたものであるが
、第6図に示す例は、外科的な縫合部51の縫合糸52
を刺激用電極として使用するものである。この場合には
、縫合部51に創傷治療剤を塗り、図示の如くリード線
53を使って各縫合糸52を電気刺激装置54に電気的
に接続して電気刺激を与えるものである。図示の例では
各縫合糸52を個別に電気刺激装置54に接続している
が、1本のリード線により各縫合糸52及び電気刺激装
置54間を接続してもよいことは勿論である。In all of the above examples, a wound treatment agent is applied to the wound area and a stimulation electrode is placed to cover the wound area, but the example shown in FIG. suture thread 52
is used as a stimulation electrode. In this case, a wound treatment agent is applied to the sutured portion 51, and each suture thread 52 is electrically connected to an electrical stimulation device 54 using a lead wire 53 as shown in the figure to apply electrical stimulation. In the illustrated example, each suture thread 52 is individually connected to the electrical stimulation device 54, but it goes without saying that each suture thread 52 and the electrical stimulation device 54 may be connected by a single lead wire.
上記の如く本発明は、種々の形状の電極を用い、創傷治
療剤と併用して電気刺激を与えるものであるが、この電
気刺激としては、先に述べたように微弱な直流電流(電
圧)、交流電流(電圧)、パルス電流(電圧)などを用
いることができ、本願の発明者によるこれまでの例では
、いずれにても治療効果は顕著である。直流における刺
激の極性は創傷側を負とし、刺激電流値は、およそ2μ
A〜500μ八程度である。また、パルスの刺激では、
例えばパルス巾を0.1〜1 m s e cに設定し
、その周波数を20Hzにして負性矩形波を創傷部位に
与え、交流刺激では、1〜10Hzの正′ 弦波を用い
ることができる。As described above, the present invention uses electrodes of various shapes to provide electrical stimulation in combination with wound treatment agents, but as described above, this electrical stimulation uses a weak direct current (voltage) , alternating current (voltage), pulsed current (voltage), etc. can be used, and in the examples given so far by the inventor of the present application, the therapeutic effect is remarkable with any of them. The polarity of direct current stimulation is negative on the wound side, and the stimulation current value is approximately 2μ.
It is about A~500μ8. In addition, with pulse stimulation,
For example, by setting the pulse width to 0.1 to 1 msec and setting the frequency to 20 Hz, a negative square wave can be applied to the wound site, and for alternating current stimulation, a sine wave of 1 to 10 Hz can be used. .
第7図は直流刺激の場合における電気刺激発生回路の構
成例を示す図、第8図はパルス刺激の場合における電気
刺激発生回路の構成例を示す図である。FIG. 7 is a diagram showing an example of the configuration of an electrical stimulation generation circuit in the case of direct current stimulation, and FIG. 8 is a diagram showing an example of the configuration of the electrical stimulation generation circuit in the case of pulse stimulation.
直流刺激の場合には、先に述べたようにおよそ2μA〜
500μへの微弱な電流値となり、第7図に示すように
電界効果トランジスタFETと抵抗Rによる簡単な回路
により構成し、正の電位側を不関電極に接続し、負の電
位側を刺激電極に接続するように構成することができる
。In the case of direct current stimulation, as mentioned earlier, approximately 2 μA ~
The current value is weak to 500μ, and as shown in Figure 7, it is constructed with a simple circuit consisting of a field effect transistor FET and a resistor R, and the positive potential side is connected to the indifferent electrode, and the negative potential side is connected to the stimulation electrode. can be configured to connect to.
また、パルス刺激の場合には、第8図に示すように発振
回路と定電流回路からなり、定電流回路を通して発振回
路の出力を刺激電極に供給することによって、発振回路
の発振周波数に従って刺激電極と不関電極との間に一定
の大きさのパルス列を印加することができる。発振回路
は、例えば図示の如く3個のICチップ11とコンデン
サC1抵抗■R1、VH2、ダイオードからなり、コン
デンサC1抵抗VR,、VH2の時定数により発振周波
数が設定できる周知の回路を使用することができる。In the case of pulse stimulation, as shown in Figure 8, it consists of an oscillation circuit and a constant current circuit, and by supplying the output of the oscillation circuit to the stimulation electrode through the constant current circuit, the stimulation electrode A pulse train of a constant magnitude can be applied between the electrode and the indifferent electrode. The oscillation circuit consists of three IC chips 11, a capacitor C1 resistor R1, VH2, and a diode as shown in the figure, and a well-known circuit can be used in which the oscillation frequency can be set by the time constant of the capacitor C1 resistor VR, VH2. Can be done.
創傷治療剤としては、糖とカリウムと、さらに必要に応
じて、消毒剤、抗菌剤、抗生物質、抗炎症剤、ビタミン
剤、蛋白分解酵素、浸出液吸収剤、ホルモン剤、角質融
解剤、血管拡張剤、蛋白分解阻止剤、凝固剤、基剤を混
和し、また必要に応じて塩化ナトリウムなどの電解質を
添加したものを用いる。Wound treatment agents include sugar and potassium, as well as antiseptics, antibacterial agents, antibiotics, anti-inflammatory agents, vitamins, proteolytic enzymes, exudate absorbers, hormones, keratolytic agents, and vasodilators. A mixture of a proteolytic agent, a proteolytic inhibitor, a coagulant, and a base is used, and if necessary, an electrolyte such as sodium chloride is added.
糖としては、ブドウ糖、果糖、マンノースのような単糖
類、麦芽糖、焦糖、などのオリゴIl!類を目的に応じ
て用いる。Examples of sugar include monosaccharides such as glucose, fructose, and mannose, as well as oligosaccharides such as maltose and sucrose. Use types depending on the purpose.
カリウムは、塩化カリウムとして治療剤100gに対し
て80mg〜160mg程度を混合する。また、必要に
応じて混合する他の成分とその添加量(治療剤100g
中)は、例えば以下の如くである。Potassium is mixed in an amount of about 80 mg to 160 mg as potassium chloride per 100 g of the therapeutic agent. In addition, other ingredients to be mixed as necessary and their addition amount (100g of therapeutic agent)
(middle) is as follows, for example.
「消毒殺菌剤」
ポビドンヨード液 5〜10m1(商品名
イソジン液)
ポビドンヨードゲル 20〜30g(商品名
イソジンゲル)
スルファジアジン銀クリーム 10〜25g(商品名
ゲーベンクリーム)
「抗菌剤」
オフロキサシン 1〜3g(商品名タリ
ビソト)
「抗生物質」
エリスロマイシン 0.5〜3g塩酸テトラ
サイクリン 3g硫硫酸シラジオマイシン
0.5g硫酸ポリミキシンB100万単位
硫酸ゲンタマイシン 0.1 g (力価)その
他
「ビタミン剤」
ビタミン 添加量(治療剤100 g中)A
20万単位B2 (燐酸リボ
フラビンとして) 274mgB6 (塩酸ピリド
キシンとして) IgE (dl−α−トコフ
ェロールとして)2g「鎮痛剤および抗炎症剤」
di−カンフル 1gリドカイ
ン 2.5〜10%塩酸プロ力イン
2gグリテール
0.5〜5gジフェンヒドラミン 1
g「創傷治癒剤」
アラントイン 200mg「角質融
解剤」
サルチル酸 5〜10g尿素
Log「蛋白分解酵素剤」
トリプシン 200,00011IJ、M
フィブリノリジン 100.0「蛋白分
解酵素阻害剤」
トラジロール 250,000 KIE「
浸出液吸収剤」
ポリエチレングリコール 適当量「血管拡張剤
」
レシチン 39g塩酸ピロカ
ルピン 1g塩化カルプロニウム
5%次にこれまでに本願発明者が行った具
体的な治療例を説明する。第9図は褥創に対する治療効
果の例を説明するための図である。"Disinfectant and disinfectant" Povidone iodine solution 5-10ml (trade name: Isodine solution) Povidone-iodine gel 20-30g (trade name: Isodine gel) Sulfadiazine silver cream 10-25g (trade name: Goeben cream) "Antibacterial agent" Ofloxacin 1-3g (trade name: Taribisoto) ) "Antibiotics" Erythromycin 0.5-3g Tetracycline hydrochloride 3g Siladiomycin sulfate 0.5g Polymyxin B sulfate 1 million units Gentamicin sulfate 0.1 g (potency) Other "vitamin supplements" Vitamin Addition amount (therapeutic agent 100 g Middle) A
200,000 units B2 (as riboflavin phosphate) 274 mg B6 (as pyridoxine hydrochloride) IgE (as dl-alpha-tocopherol) 2 g "Analgesic and anti-inflammatory agent" di-camphor 1 g lidocaine 2.5-10% propyridine hydrochloride 2 g Glytail
0.5-5g diphenhydramine 1
g “Wound healing agent” Allantoin 200mg “Keratolytic agent” Salicylic acid 5-10g Urea
Log “Proteolytic enzyme agent” Trypsin 200,00011IJ,M
Fibrinolysin 100.0 “Proteolytic enzyme inhibitor” Trasylol 250,000 KIE “
Exudate absorbent” Polyethylene glycol Appropriate amount “Vasodilator” Lecithin 39g Pilocarpine hydrochloride 1g Carpronium chloride
5% Next, specific examples of treatments performed by the inventor of the present application will be explained. FIG. 9 is a diagram for explaining an example of the therapeutic effect on bedsores.
5患者は、40才台の男性であって、第7頚髄損傷によ
る四肢麻痺で、左殿部擦過傷のところより化膿し、再開
となった。従来の方法による治療を受けるが軽快せず、
本発明の電気刺激治療方法による治療を行った。再開の
程度は、第9図(a)に示すように皮膚に直径3cmの
円形に穴があき、深さ5cmで坐骨(坐骨結節)61に
達する潰瘍を形成し、しかも、潰瘍は、図示の如く上下
方向にも延びて複雑な洞を形成していた。褥創部からは
聴性浸出液が大量に出ており、衣類を通して車椅子の座
蒲団まで濡れる程であり、しかも強い悪臭を発していた
。Patient 5 was a man in his 40s who had quadriplegia due to an injury to the 7th cervical spinal cord, and his left buttock abrasion developed suppuration and was restarted. Despite receiving treatment using conventional methods, the condition did not improve.
Treatment was performed using the electrical stimulation treatment method of the present invention. As shown in Figure 9(a), the degree of reopening is as follows: a circular hole with a diameter of 3 cm is made in the skin, and an ulcer is formed that reaches the ischium (ischial tuberosity) 61 at a depth of 5 cm; It extended vertically as well, forming a complex sinus. A large amount of audible exudate was coming out from the bedsore, so much so that it soaked through his clothes and even the mattress of his wheelchair, and it also emitted a strong odor.
そこで、まず、褥創部を生理食塩水で洗った後、ステン
レスファイバー類の刺激用電極を創部に挿入し、ついで
除菌物質として消毒剤であるゲーベン(スルファジアジ
ン銀)の入った創傷治療剤を塗り込み、不関電極は側腹
部に貼り付けた。電気刺激としては10μAの直流電流
を常時流し、褥創部は1日4回処置した。Therefore, first, after washing the bed sore with physiological saline, a stimulation electrode made of stainless steel fibers is inserted into the wound, and then a wound treatment agent containing Goeben (silver sulfadiazine), a disinfectant, is applied as an antibacterial agent. The indifferent electrode was attached to the flank. For electrical stimulation, a direct current of 10 μA was constantly applied, and the bedsore was treated four times a day.
治療開始翌日より、黒紫色だった創部に赤みが出てきて
浸出液の悪臭が弱まると共に、量も減少するのが認めら
れた。そして治療効果は日に日に目に見えて現れ4日後
には、浸出液の量は1/3程度に減少すると共に悪臭は
全く消失し液も完全に透明となった。この時点で細菌検
査を施行して薬物への感受性試験を行ったところ、クリ
ビット(抗菌剤)に対して最も強い感受性を示したので
、除菌剤をクリビットに変更した。肉芽組織の増殖及び
血管の増生も治療開始5日目には明瞭に見ることができ
た。From the day after the start of treatment, redness appeared in the wound, which had previously been blackish-purple, and the odor of the exudate weakened, and the amount of exudate decreased. The therapeutic effect became visible day by day, and after 4 days, the amount of exudate had decreased to about 1/3, the bad odor had completely disappeared, and the liquid had become completely clear. At this point, we conducted a bacterial test and tested for drug susceptibility, and as it showed the highest sensitivity to Krivit (an antibacterial agent), we changed the disinfectant to Krivit. Proliferation of granulation tissue and proliferation of blood vessels could also be clearly seen on the 5th day after the start of treatment.
治療開始後15日になると、第9図(ト))に示すよう
に皮膚開口部の直径は最初の半分の1.5cmに縮小し
、肉芽組織66の増殖も活発で、はじめ完全に露出して
いた坐骨61が肉芽組織で覆われるまでになった。しか
も菌は全く検出されず、浸出液も創部の当てガーゼが濡
れる程度まで減少してきた。この治療速度は、これまで
の治療法では達しえなかった最も早いものである。Fifteen days after the start of treatment, the diameter of the skin opening has shrunk to 1.5 cm, half of the initial diameter, as shown in FIG. The ischium 61, which had previously been damaged, is now covered with granulation tissue. Furthermore, no bacteria were detected, and the amount of exudate had decreased to the extent that the gauze applied to the wound was wet. This treatment speed is the fastest that has not been achieved with previous treatments.
なお、本発明は、上記の実施例に限定されるものではな
く、種々の変形が可能である。例えば上記の実施例では
、創傷治療剤を併用して電気刺激を与えるようにしたが
、例えば創傷治療剤が使用できない患部に電気刺激だけ
でを与えても高い治癒効果が得られる。従って、創傷治
療剤を併用せず、電気刺激のみを与えるように構成した
ものでもよい。糖とカリウムを主として目的に応じて様
々な薬剤を混合した組成よりなる創傷治療剤を併用した
が、この混合する薬剤は、上記の実施例で列挙したもの
以外の薬剤であってもよいし、上記の具体的な治療例で
述べたように治療の経過に応じて、或いは症状に応じて
創傷治療剤の成分を変えてもよいことはいうまでもない
。また、第7図や第8図に示すような電気回路は、定電
流回路や発振回路として周知の他の回路を使用してもよ
いことはいうまでもない。Note that the present invention is not limited to the above embodiments, and various modifications are possible. For example, in the above embodiment, electrical stimulation was applied in combination with a wound treatment agent, but a high healing effect can also be obtained by applying electrical stimulation alone to an affected area where a wound treatment agent cannot be used. Therefore, it may be configured to apply only electrical stimulation without using a wound treatment agent in combination. A wound treatment agent consisting mainly of sugar and potassium mixed with various drugs depending on the purpose was used, but the mixed drug may be a drug other than those listed in the above examples. It goes without saying that the ingredients of the wound treatment agent may be changed depending on the progress of the treatment or the symptoms as described in the above specific treatment examples. It goes without saying that other circuits known as constant current circuits or oscillation circuits may be used as the electric circuits shown in FIGS. 7 and 8.
以上の説明から明らかなように、本発明によれば、皮膚
や神経組織等の組織再生に必須な糖やカリウムを損傷部
位に与えると共に併せて電気刺激を与えるので、従来の
治療方法に比べて顕著な効果のある治療方法及び治療装
置を提供することができる。先に述べたように糖は、近
年になり重度の再開に対して、顕著な肉芽形成効果があ
るとして再開治療剤に使われ始め、また、電気刺激も骨
折の治療に有効なことが知られているが、本発明に係る
電気刺激治療方法及び治療装置は、このような従来の治
療剤や治療法の域をもかに越える治療効果を得ることが
できるものである。As is clear from the above explanation, according to the present invention, sugar and potassium, which are essential for tissue regeneration such as skin and nerve tissues, are supplied to the injured area, and electrical stimulation is also applied, so compared to conventional treatment methods. A treatment method and treatment device with significant effects can be provided. As mentioned earlier, sugar has recently begun to be used as a treatment agent for severe fractures, as it has a remarkable granulation-forming effect, and electrical stimulation is also known to be effective in treating fractures. However, the electrical stimulation treatment method and treatment device according to the present invention can provide therapeutic effects that far exceed those of such conventional therapeutic agents and treatment methods.
第1図は本発明に係る電気刺激創傷治療装置の1実施例
を説明するための図、第2図は本発明に係る電気刺激創
傷治療装置の他の実施例を説明するための図、第3図は
シート状の刺激用電極による治療例を示す図、第4図は
糸状の刺激用電極による治療例を示す図、第5図は電極
の形状例を示す図、第6図は外科的に縫合した部分の治
療例を示す図、第7図は直流刺激の場合における電気刺
激発生回路の構成例を示す図、第8図はパルス刺激の場
合における電気刺激発生回路の構成例を示す図、第9図
は再開に対する治療効果の例を説明するための図である
。
1と14・・・不関電極、2と13・・・刺激用電極、
3・・・シート電池、4・・・電気刺激回路、11・・
・電気刺激装置、12と15・・・コネクタ、16・・
・治療部位、21と31・・・覆い、22・・・刺激用
電極、23と33・・・創傷治療剤、32・・・糸状電
極、41・・・ファイバー露出部、42・・・被覆、4
3・・・コネクタ部、51・・・縫合部、52・・・縫
合糸、53・・・リード線、54・・・電気刺激装置。
出 願 人 新技術開発事業団
代理人 弁理士 阿 部 龍 吉
〜!=
ゑ −s。FIG. 1 is a diagram for explaining one embodiment of the electrical stimulation wound treatment device according to the present invention, FIG. 2 is a diagram for explaining another embodiment of the electrical stimulation wound treatment device according to the present invention, and FIG. Figure 3 is a diagram showing an example of treatment using a sheet-shaped stimulation electrode, Figure 4 is a diagram showing an example of treatment using a thread-shaped stimulation electrode, Figure 5 is a diagram showing an example of the shape of the electrode, and Figure 6 is a diagram showing a surgical example. 7 is a diagram showing an example of the configuration of an electrical stimulation generation circuit in the case of direct current stimulation, and FIG. 8 is a diagram showing an example of the configuration of the electrical stimulation generation circuit in the case of pulse stimulation. , FIG. 9 is a diagram for explaining an example of the therapeutic effect on restart. 1 and 14...indifferent electrodes, 2 and 13...stimulation electrodes,
3... Sheet battery, 4... Electric stimulation circuit, 11...
・Electrical stimulation device, 12 and 15...Connector, 16...
・Treatment area, 21 and 31... Cover, 22... Stimulation electrode, 23 and 33... Wound treatment agent, 32... Thread-like electrode, 41... Fiber exposed part, 42... Cover , 4
3... Connector part, 51... Suture part, 52... Suture thread, 53... Lead wire, 54... Electric stimulation device. Applicant: New Technology Development Corporation Agent, Patent Attorney: Ryukichi Abe! = ゑ −s.
Claims (10)
される不関電極、及び刺激電極と不関電極との間に電気
刺激を与える刺激信号発生手段からなることを特徴とす
る電気刺激創傷治療装置。(1) Electrical stimulation characterized by comprising a stimulation electrode used on the treated area, an indifferent electrode placed opposite to the stimulation electrode, and a stimulation signal generating means for applying electrical stimulation between the stimulation electrode and the indifferent electrode. Wound treatment equipment.
ことを特徴とする特許請求の範囲第1項記載の電気刺激
創傷治療装置。(2) The electrical stimulation wound treatment device according to claim 1, characterized in that one or more filamentous electrodes are used as the stimulation electrodes.
たことを特徴とする特許請求の範囲第2項記載の電気刺
激創傷治療装置。(3) The electrical stimulation wound treatment device according to claim 2, characterized in that a plurality of thread-like electrodes are arranged radially from the corners of the rectangular surface.
特許請求の範囲第1項記載の電気刺激創傷治療装置。(4) The electrical stimulation wound treatment device according to claim 1, characterized in that a suture thread is used as a stimulation electrode.
を電源として刺激信号を生成する信号発生回路からなる
ことを特徴とする特許請求の範囲第1項記載の電気刺激
創傷治療装置。(5) The electrical stimulation wound treatment device according to claim 1, wherein the stimulation signal generation means comprises a sheet battery and a signal generation circuit that generates stimulation signals using the sheet battery as a power source.
として発生することを特徴とする特許請求の範囲第1項
記載の電気刺激創傷治療装置。(6) The electrical stimulation wound treatment device according to claim 1, wherein the stimulation signal generating means generates a weak direct current as the stimulation signal.
号として発生することを特徴とする特許請求の範囲第1
項記載の電気刺激創傷治療装置。(7) The stimulation signal generating means generates a weak pulse current as the stimulation signal, as claimed in claim 1.
The electrical stimulation wound treatment device described in Section 1.
のシートに一体構成し、貼着可能にしたことを特徴とす
る特許請求の範囲第1項記載の電気刺激創傷治療装置。(8) The electrical stimulation wound treatment device according to claim 1, characterized in that the stimulation electrode, the indifferent electrode, and the stimulation signal generation means are integrated into one sheet and can be attached.
傷治療剤を使用することを特徴とする特許請求の範囲第
1項記載の電気刺激創傷治療装置。(9) The electrical stimulation wound treatment device according to claim 1, characterized in that a wound treatment agent containing at least sugar and potassium is used together with the stimulation electrode.
消毒剤、抗菌剤、抗生物質、抗炎症剤、ビタミン剤、蛋
白分解酵素、浸出液吸収剤、ホルモン剤、角質融解剤、
血管拡張剤、蛋白分解阻止剤、凝固剤、基剤を選択的に
混和し、また、塩化ナトリウム等の電解質を添加したも
のを用いることを特徴とする特許請求の範囲第9項記載
の電気刺激創傷治療装置。(10) Sugar and potassium as a wound treatment agent, and
Disinfectants, antibacterial agents, antibiotics, anti-inflammatory agents, vitamins, proteolytic enzymes, exudate absorbers, hormones, keratolytic agents,
The electrical stimulation according to claim 9, characterized in that a vasodilator, a proteolytic inhibitor, a coagulant, and a base are selectively mixed together, and an electrolyte such as sodium chloride is added. Wound treatment equipment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6192987A JPS63229068A (en) | 1987-03-17 | 1987-03-17 | Electric stimulation wound treatment apparatus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6192987A JPS63229068A (en) | 1987-03-17 | 1987-03-17 | Electric stimulation wound treatment apparatus |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63229068A true JPS63229068A (en) | 1988-09-22 |
JPH0472556B2 JPH0472556B2 (en) | 1992-11-18 |
Family
ID=13185342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6192987A Granted JPS63229068A (en) | 1987-03-17 | 1987-03-17 | Electric stimulation wound treatment apparatus |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63229068A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06178815A (en) * | 1990-11-01 | 1994-06-28 | Robert Tapper | Ion introducing therapeutic system |
JPH0938214A (en) * | 1995-08-02 | 1997-02-10 | Agency Of Ind Science & Technol | Wound covering material for skin |
JP2007530090A (en) * | 2003-07-14 | 2007-11-01 | パワー ペーパー リミティド | Method, apparatus and kit for treating onychomycosis using electrokinetic transport of substances |
JP2013500839A (en) * | 2009-08-05 | 2013-01-10 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Surgical wound covering incorporating connecting hydrogel beads with electrodes embedded therein |
JP2020199271A (en) * | 2014-12-17 | 2020-12-17 | エム.モワー モートン | Method and apparatus for improved wound healing |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5918067A (en) * | 1982-07-21 | 1984-01-30 | Nissan Motor Co Ltd | Sealing construction along sun roof frame periphery |
JPS59108566A (en) * | 1975-02-10 | 1984-06-23 | サイブロン・コ−ポレ−シヨン | Prevention of contamination of silver containing electrode of weak dc current treating apparatus |
JPS60178819A (en) * | 1984-02-24 | 1985-09-12 | Yazaemon Hasegawa | Antitrichophytial agent for external use |
JPS60222425A (en) * | 1984-02-24 | 1985-11-07 | ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア | Wound therapy |
JPS61146271A (en) * | 1984-12-20 | 1986-07-03 | ワコ−トレ−デイング株式会社 | Adhesive drug |
JPS61246130A (en) * | 1985-04-24 | 1986-11-01 | Japan Fine Chem Kk | External agent for stimulation skin cell activity |
-
1987
- 1987-03-17 JP JP6192987A patent/JPS63229068A/en active Granted
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59108566A (en) * | 1975-02-10 | 1984-06-23 | サイブロン・コ−ポレ−シヨン | Prevention of contamination of silver containing electrode of weak dc current treating apparatus |
JPS5918067A (en) * | 1982-07-21 | 1984-01-30 | Nissan Motor Co Ltd | Sealing construction along sun roof frame periphery |
JPS60178819A (en) * | 1984-02-24 | 1985-09-12 | Yazaemon Hasegawa | Antitrichophytial agent for external use |
JPS60222425A (en) * | 1984-02-24 | 1985-11-07 | ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア | Wound therapy |
JPS61146271A (en) * | 1984-12-20 | 1986-07-03 | ワコ−トレ−デイング株式会社 | Adhesive drug |
JPS61246130A (en) * | 1985-04-24 | 1986-11-01 | Japan Fine Chem Kk | External agent for stimulation skin cell activity |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06178815A (en) * | 1990-11-01 | 1994-06-28 | Robert Tapper | Ion introducing therapeutic system |
JPH0938214A (en) * | 1995-08-02 | 1997-02-10 | Agency Of Ind Science & Technol | Wound covering material for skin |
JP2007530090A (en) * | 2003-07-14 | 2007-11-01 | パワー ペーパー リミティド | Method, apparatus and kit for treating onychomycosis using electrokinetic transport of substances |
JP2013500839A (en) * | 2009-08-05 | 2013-01-10 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Surgical wound covering incorporating connecting hydrogel beads with electrodes embedded therein |
JP2020199271A (en) * | 2014-12-17 | 2020-12-17 | エム.モワー モートン | Method and apparatus for improved wound healing |
Also Published As
Publication number | Publication date |
---|---|
JPH0472556B2 (en) | 1992-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goldin et al. | The effects of Diapulse on the healing of wounds: a double-blind randomised controlled trial in man | |
US4846181A (en) | Soft tissue wound healing therapy utilizing pulsed electrical stimulation | |
Kloth et al. | Acceleration of wound healing with high voltage, monophasic, pulsed current | |
Stiller et al. | A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double‐blind, placebo‐controlled clinical trial | |
Polak et al. | High-voltage pulsed current electrical stimulation in wound treatment | |
Balakatounis et al. | Low-intensity electrical stimulation in wound healing: review of the efficacy of externally applied currents resembling the current of injury | |
Modaghegh et al. | Use of phenytoin in healing of war and non‐war wounds: A pilot study of 25 cases | |
US20050033387A1 (en) | Procedure and machine for electro-inducing/stimulating deep layered muscle contractions using a biphasic faradic pulse sequence | |
Franek et al. | Modern application of high voltage stimulation for enhanced healing of venous crural ulceration | |
DE59607342D1 (en) | Use of proline as the only therapeutic agent for the manufacture of a medicament for the treatment of rheumatic diseases and chronic and traumatic pain | |
Solotoff | Treatment for pitted acne scarring-postauricular punch grafts followed by dermabrasion | |
Ahmad | High-voltage pulsed galvanic stimulation: effect of treatment duration on healing of chronic pressure ulcers | |
Hampton et al. | Healing an intractable wound using bio-electrical stimulation therapy | |
CA2389134C (en) | Electromagnetic method of treatment of lesions associated with inadequate blood perfusion, partial denervation, tissue loss, pain edema, inflammation and infection | |
JPS63229068A (en) | Electric stimulation wound treatment apparatus | |
Fraccalvieri et al. | Electrical stimulation for difficult wounds: only an alternative procedure? | |
Todd et al. | Treatment of chronic varicose ulcers with pulsed electromagnetic fields: a controlled pilot study | |
RU2423118C1 (en) | Method of treating trophic ulcers | |
Niezgoda et al. | Wound treatment options | |
Ricci et al. | The effect of stochastic electrical noise on hard-to-heal wounds | |
Jensen | Treatment of pressure sores | |
Morris | Bio-electrical stimulation therapy using POSiFECT® RD | |
Sussman | Electrical stimulation | |
JPS63215631A (en) | Wound remedy | |
Tiqwa | The effect of stochastic electrical noise on hard-to-heal wounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |